本文選題：益生菌 + 非酒精性脂肪肝��； 參考：《山東醫(yī)藥》2015年07期

【摘要】：目的系統(tǒng)評(píng)價(jià)益生菌制劑對(duì)非酒精性脂肪性肝病(NAFLD)的療效。方法檢索2014年5月之前在Pub Med、Springer Link、CNKI中文期刊全文數(shù)據(jù)庫、維普中文科技期刊數(shù)據(jù)庫網(wǎng)及萬方數(shù)據(jù)庫中發(fā)表的文獻(xiàn),選取關(guān)于益生菌制劑治療NAFLD的隨機(jī)對(duì)照試驗(yàn),由2名研究者獨(dú)立對(duì)文獻(xiàn)進(jìn)行質(zhì)量評(píng)價(jià)和數(shù)據(jù)提取,應(yīng)用Rev Man5.1軟件進(jìn)行Meta分析。連續(xù)性變量計(jì)量單位相同采用加權(quán)均數(shù)差(WMD)進(jìn)行評(píng)估。結(jié)果共納入8項(xiàng)符合標(biāo)準(zhǔn)的隨機(jī)對(duì)照試驗(yàn)相關(guān)文獻(xiàn),NAFLD患者共543。Meta分析顯示:與對(duì)照組相比,益生菌制劑能明顯降低NAFLD患者的ALT(WMD=17.74,95%CI:12.23~23.14,P0.000 01)、AST(WMD=9.01,95%CI:8.13~9.89,P0.000 01)、GGT(WMD=16.48,95%CI:1.91~31.05,P=0.03)、CHO(WMD=0.24,95%CI:0.16~0.31,P0.000 01)和TG(WMD=0.29,95%CI:0.13~0.45,P=0.000 4)水平,不能改善BMI(WMD=0.04,95%CI:-0.48~0.57,P=0.87)。結(jié)論益生菌制劑可降低NAFLD患者ALT、AST、GGT、CHO和TG水平,促進(jìn)肝功能的恢復(fù),但對(duì)患者的BMI無改善作用。
[Abstract]:Objective to evaluate the efficacy of probiotics in the treatment of nonalcoholic fatty liver disease (NAF LDD). Methods to search the literature published in the Chinese journal full-text database of Pub Medtrol Springer Linkr Linki before May 2014, the database network of Chinese scientific and technological journals of Weipu and Wanfang database, and to select a randomized controlled trial of probiotics in treating NAFLD. The quality evaluation and data extraction of the literature were carried out by two researchers independently, and Meta analysis was carried out by using Rev Man5.1 software. The same unit of measurement of continuous variables was evaluated using weighted mean difference (WMD). 緇撴灉鍏辯撼鍏，

本文編號(hào)：1914083